A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A
Open Access
- 9 January 2024
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 112 (5) , 756-764
Abstract
Introduction: The safety and efficacy of the extended half‐life factor VIII (FVIII) product damoctocog alfa pegol (BAY 94‐9027, Jivi®) has been demonstrated in the PROTECT VIII Kids study (NCT01775618), where male previously‐treated patients (PTPs) aged <12 years old with severe haemophilia A and ≥ 50 exposure days (EDs) were treated prophylactically. The PROTECT VIII Kids extension study assessed the long‐term safety and efficacy of damoctocog alfa pegol in the same population. Aim: To evaluate the long‐term impact of damoctocog alfa pegol in a post hoc subgroup analysis of adolescent patients in the PROTECT VIII Kids study and its extension from 12th birthday onwards. Methods: The current analysis included PTPs aged ≥12 years old, who remained in the extension for ≥6 months following their 12th birthday. The observation period was defined as the time from 12th birthday to the end of the extension period; all data from this birthday were included whether in the main study or extension phase. The main efficacy variable was annualised bleeding rate (ABR) and the main safety variable was the frequency of inhibitor development. Results: This subgroup analysis comprised 25 patients. Median observation time after 12th birthday was 3.2 years. Median total/joint/spontaneous ABRs in the observation period were 1.7/0.7/0.3, respectively. Safety findings were consistent with those reported for the overall study population; no confirmed FVIII inhibitors or anti‐drug antibodies were reported. Conclusions: Damoctocog alfa pegol is efficacious with a favourable safety profile in adolescents with haemophilia A, supporting its long‐term use in children and adolescents.Keywords
Funding Information
- Bayer
This publication has 36 references indexed in Scilit:
- Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia AJournal of Thrombosis and Haemostasis, 2015
- Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimensBlood, 2015
- Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER studyThrombosis and Haemostasis, 2015
- Treatment decision‐making among Canadian youth with severe haemophilia: a qualitative approachHaemophilia, 2014
- Better adherence to prescribed treatment regimen is related to less chronic pain among adolescents and young adults with moderate or severe haemophiliaHaemophilia, 2014
- Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia AJournal of Thrombosis and Haemostasis, 2014
- Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weightBlood, 2012
- Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatmentBlood, 2010
- Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimensJournal of Thrombosis and Haemostasis, 2010
- Practice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia, 2006